Halozyme Therapeutics, Inc.
HALO
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other tā¦ read more
Healthcare
Biotechnology
21 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$63.66
Price+0.16%
$0.10
1Y
Price
Market Cap
$7.513b
Mid
Price/Earnings 3y Avg5y Avg
24.9x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+62.2%
EBITDA Margin-31.3%
Net Profit Margin+48.2%
Free Cash Flow Margin+62.2%
EBITDA Margin-31.3%
Net Profit Margin+48.2%
Free Cash Flow MarginRevenue
$1.397b
+37.6%
1y CAGR+28.5%
3y CAGR+33.6%
5y CAGREarnings
$316.889m
-28.6%
1y CAGR+22.8%
3y CAGR+4.6%
5y CAGREPS
$2.56
-27.4%
1y CAGR+27.3%
3y CAGR+8.6%
5y CAGRBook Value
$48.814m
$2.525b
Assets$2.477b
Liabilities-
DebtDebt to Assets
0.0%
-
Debt to EBITDAFree Cash Flow
$644.588m
+37.6%
1y CAGR+40.6%
3y CAGR+25.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company